Roche Returns Diabetes Drug Rights to Ipsen Because of Side Effects

Roche Holding AG returned rights to the experimental diabetes drug taspoglutide to developer Ipsen SA after patients dropped out of trials because of side effects, according to two people with knowledge of the matter.
Bloomberg